{
    "clinical_study": {
        "@rank": "100907", 
        "arm_group": [
            {
                "arm_group_label": "Tolvaptan Early Withdrawal", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Tolvaptan Late Withdrawal", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to demonstrate that tolvaptan effectively and safely increases\n      and maintains serum sodium concentrations in children and adolescent subjects with euvolemic\n      or hypervolemic hypernatremia."
        }, 
        "brief_title": "Study of the Safety and Effectiveness of SAMSCA\u00ae (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyponatremia", 
        "condition_browse": {
            "mesh_term": "Hyponatremia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          -  Male and female subjects \u2265 4 weeks (or \u226544 weeks adjusted gestational age for\n             premature births) to <18 years old\n\n          -  Subjects hospitalized with euvolemic or hypervolemic hyponatremia resistant to\n             initial standard background therapy\n\n          -  Persistent euvolemic or hypervolemic hyponatremia\n\n          -  Ability to maintain adequate fluid intake (orally or IV)\n\n        Exclusion:\n\n          -  Evidence of hypovolemia or intravascular volume depletion\n\n          -  Serum sodium < 120 mmol/L\n\n          -  Use of potent CYP3A4 inhibitors in subjects \u2264 50 kg or moderate CYP3A4 inhibitors in\n             subjects < 20 kg\n\n          -  Lacks free access to water or without ICU-level fluid monitoring and management\n\n          -  History or current diagnosis of nephrotic syndrome\n\n          -  Transient hyponatremia likely to resolve\n\n          -  Hyperkalemia\n\n          -  eGFR < 30 mL/min/1.73 m\u00b2\n\n          -  Acute kidney injury\n\n          -  Severe or acute neurological symptoms requiring other intervention\n\n          -  Prior treatment for hyponatremia with hypertonic saline within 8 hours of qualifying\n             serum sodium assessments; Urea, lithium, demeclocycline, conivaptan, or tolvaptan\n             within 4 days of qualifying serum sodium assessments\n\n          -  Anuria or urinary outflow obstruction\n\n          -  History of hypersensitivity and/or idiosyncratic reaction to benzazepine derivatives\n\n          -  Psychogenic polydipsia\n\n          -  Uncontrolled diabetes mellitus\n\n          -  Screening liver function values > 3 x ULN\n\n          -  Deficient coagulation\n\n          -  Hyponatremia due to the result of any medication that can safely be withdrawn or that\n             is most appropriately corrected by alternative therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012959", 
            "org_study_id": "156-08-276", 
            "secondary_id": "2013-002005-59"
        }, 
        "intervention": {
            "arm_group_label": [
                "Tolvaptan Early Withdrawal", 
                "Tolvaptan Late Withdrawal"
            ], 
            "intervention_name": "Tolvaptan", 
            "intervention_type": "Drug", 
            "other_name": "SAMSCA\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hyponatremia", 
            "Euvolemic", 
            "Hypervolemic", 
            "Serum sodium", 
            "Dilutional hyponatremia", 
            "Electrolyte abnormality", 
            "Electrolyte imbalance", 
            "Metabolic disease"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA \u00ae (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia", 
        "other_outcome": [
            {
                "description": "Change in serum sodium from 24 hours post-last dose to 14 days post-randomization.", 
                "measure": "Change in serum sodium from 24 hours post-last dose to 14 days post-randomization.", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Vital Signs of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "measure": "Vital Signs of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Tolvaptan maximum (peak) plasma concentration, time to max (peak) plasma concentration, and area under the concentration-time curve from time zero to 24 hours.", 
                "measure": "Tolvaptan plasma concentration.", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Body Weight of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "measure": "Body Weight of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Blood Pressure of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "measure": "Blood Pressure of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Clinical Laboratory Tests of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "measure": "Clinical Laboratory Tests of Potential Clinical Relevance - Mean Change from Baseline to study completion.", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Fluid intake every 6 hours on Days 1 and 2 (Phase A).", 
                "measure": "Fluid intake.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1/2"
            }, 
            {
                "description": "Urine output every 6 hours on Days 1 and 2 (Phase A).", 
                "measure": "Urine output.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1/2"
            }, 
            {
                "description": "Fluid balance (intake - output) every 6 hours on Days 1 and 2 (Phase A).", 
                "measure": "Fluid balance.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1/2"
            }
        ], 
        "overall_contact": {
            "email": "Jeanette.george@incresearch.com", 
            "last_name": "Jeanette George", 
            "phone": "919-926-5965"
        }, 
        "overall_contact_backup": {
            "email": "Simona.Ripamonti@incresearch.com", 
            "last_name": "Simona Ripamonti", 
            "phone": "39 02 96199248"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
            "last_name": "Ann Dandurand, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in serum sodium concentration.", 
            "measure": "Change in serum sodium concentration.", 
            "safety_issue": "No", 
            "time_frame": "Day 2/3, Day 4/5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012959"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in serum sodium concentration at the end of Day 2/3 from baseline in Phase A.", 
                "measure": "Change in serum sodium concentration.", 
                "safety_issue": "No", 
                "time_frame": "Day 2/3"
            }, 
            {
                "description": "Percentage of subjects with overly rapid increase in serum sodium (\u226512 mmol/L in 24 hours after 1st dose).", 
                "measure": "Overly rapid increase in serum sodium.", 
                "safety_issue": "Yes", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "Percentage of subjects requiring rescue medication during Phase A and Phase B of the trial.", 
                "measure": "Percentage of subjects requiring rescue medication.", 
                "safety_issue": "Yes", 
                "time_frame": "Days 4/5"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "INC Research", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}